Marshall Financial Group LLC Purchases Shares of 17,663 Exact Sciences Corporation $EXAS

Key Points

• Marshall Financial Group LLC acquired a new stake of 17,663 shares in Exact Sciences (NASDAQ:EXAS) during Q4, valued at about $1.79 million.
• Institutional investors now own 88.82% of EXAS, with large funds materially increasing positions — Ameriprise added 2.31 million shares and now holds 4.49 million shares (~$245.8M).
• Exact Sciences posted Q4 EPS of -$0.21 (missing estimates) while revenue of $878.4M rose 23.1% y/y and beat expectations; the stock trades near ~$105 despite analysts' average price target of $92.13 and a consensus Reduce/Hold view.

Marshall Financial Group LLC acquired a new stake in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,663 shares of the medical research company's stock, valued at approximately $1,794,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. increased its position in Exact Sciences by 105.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company's stock valued at $245,802,000 after buying an additional 2,310,139 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Exact Sciences by 31.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company's stock worth $213,889,000 after acquiring an additional 939,888 shares in the last quarter. Holocene Advisors LP boosted its holdings in Exact Sciences by 27.0% in the third quarter. Holocene Advisors LP now owns 2,725,390 shares of the medical research company's stock worth $149,106,000 after acquiring an additional 580,209 shares in the last quarter. William Blair Investment Management LLC grew its stake in Exact Sciences by 26.5% in the third quarter. William Blair Investment Management LLC now owns 2,555,051 shares of the medical research company's stock valued at $139,787,000 after acquiring an additional 534,881 shares during the period. Finally, Champlain Investment Partners LLC grew its stake in Exact Sciences by 12.6% in the second quarter. Champlain Investment Partners LLC now owns 2,529,820 shares of the medical research company's stock valued at $134,435,000 after acquiring an additional 282,825 shares during the period. Institutional investors own 88.82% of the company's stock.

Exact Sciences Stock Up 1.0%

Exact Sciences stock opened at $104.91 on Monday. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $104.98. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The firm's 50-day simple moving average is $103.06 and its 200 day simple moving average is $86.11. The stock has a market cap of $20.03 billion, a PE ratio of -95.37, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The firm had revenue of $878.38 million for the quarter, compared to the consensus estimate of $860.59 million. During the same period in the prior year, the business earned ($0.06) EPS. Exact Sciences's quarterly revenue was up 23.1% compared to the same quarter last year. Research analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

EXAS has been the topic of a number of research reports. TD Cowen lowered Exact Sciences from a "buy" rating to a "hold" rating in a research report on Tuesday, November 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Exact Sciences in a research report on Thursday, January 22nd. Evercore set a $105.00 price target on shares of Exact Sciences and gave the company an "in-line" rating in a research note on Monday, January 5th. Mizuho restated a "neutral" rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a report on Tuesday, January 20th. Finally, Jefferies Financial Group lowered shares of Exact Sciences from a "buy" rating to a "hold" rating and raised their price objective for the company from $90.00 to $105.00 in a research note on Monday, November 24th. Twenty-one investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Exact Sciences currently has an average rating of "Reduce" and an average price target of $92.13.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.